Current status of PTP-based therapeutics

Rongjun He, Zhong-Yin Zhang

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Protein tyrosine phosphorylation regulates virtually all aspects of cellular function. Proper levels of protein tyrosine phosphorylation are controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs). Deregulation of tyrosine phosphorylation-mediated signaling is a major cause of cancer. Indeed, PTKs represent an important class of anti-cancer drug targets with more than 20 drugs already approved by the FDA. Several PTPs are also implicated in tumor onset, progression and metastasis, and have attracted attention as potential therapeutic targets for cancer treatment. The most recognized members of the PTP family include PTP1B, SHP2, CDC25, and PRLs. PTP1B plays a positive role in breast cancer progression; SHP2 germ line and somatic gain-of-function mutations cause Noonan Syndrome, juvenile myelomonocytic leukemia, acute myeloid leukemia, and solid tumors; CDC25 regulates cell cycle progression and is overexpressed in a number of human cancers; and the PRLs are overexpressed in cancer and have been linked to tumor metastasis. Hence, inhibitors directed against these PTPs can serve as potential novel anti-cancer agents. This chapter provides an overview of the mechanisms of these oncogenic PTPs in promoting cancer, the approaches for inhibitor discovery, as well as the current status of drug development targeting these phosphatases.

Original languageEnglish (US)
Title of host publicationProtein Tyrosine Phosphatases in Cancer
PublisherSpringer New York
Pages335-353
Number of pages19
ISBN (Electronic)9781493936496
ISBN (Print)9781493936472
DOIs
StatePublished - Jan 1 2016

Fingerprint

Protein Tyrosine Phosphatases
Phosphorylation
Tyrosine
Tumors
Neoplasms
Protein-Tyrosine Kinases
Pharmaceutical Preparations
Therapeutics
Oncology
Deregulation
Phosphoric Monoester Hydrolases
Proteins
Juvenile Myelomonocytic Leukemia
Cells
Noonan Syndrome
Neoplasm Metastasis
Drug Delivery Systems
Acute Myeloid Leukemia
Germ Cells
Cell Cycle

Keywords

  • Cancer
  • CDC25
  • Drug development
  • Inhibitor design
  • Potency and specificity
  • PRL
  • Protein-tyrosine phosphatase
  • PTP1B
  • SHP2
  • Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

He, R., & Zhang, Z-Y. (2016). Current status of PTP-based therapeutics. In Protein Tyrosine Phosphatases in Cancer (pp. 335-353). Springer New York. https://doi.org/10.1007/978-1-4939-3649-6_13

Current status of PTP-based therapeutics. / He, Rongjun; Zhang, Zhong-Yin.

Protein Tyrosine Phosphatases in Cancer. Springer New York, 2016. p. 335-353.

Research output: Chapter in Book/Report/Conference proceedingChapter

He, R & Zhang, Z-Y 2016, Current status of PTP-based therapeutics. in Protein Tyrosine Phosphatases in Cancer. Springer New York, pp. 335-353. https://doi.org/10.1007/978-1-4939-3649-6_13
He R, Zhang Z-Y. Current status of PTP-based therapeutics. In Protein Tyrosine Phosphatases in Cancer. Springer New York. 2016. p. 335-353 https://doi.org/10.1007/978-1-4939-3649-6_13
He, Rongjun ; Zhang, Zhong-Yin. / Current status of PTP-based therapeutics. Protein Tyrosine Phosphatases in Cancer. Springer New York, 2016. pp. 335-353
@inbook{b8ce8aed10bf40928aaaade95973c7f5,
title = "Current status of PTP-based therapeutics",
abstract = "Protein tyrosine phosphorylation regulates virtually all aspects of cellular function. Proper levels of protein tyrosine phosphorylation are controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs). Deregulation of tyrosine phosphorylation-mediated signaling is a major cause of cancer. Indeed, PTKs represent an important class of anti-cancer drug targets with more than 20 drugs already approved by the FDA. Several PTPs are also implicated in tumor onset, progression and metastasis, and have attracted attention as potential therapeutic targets for cancer treatment. The most recognized members of the PTP family include PTP1B, SHP2, CDC25, and PRLs. PTP1B plays a positive role in breast cancer progression; SHP2 germ line and somatic gain-of-function mutations cause Noonan Syndrome, juvenile myelomonocytic leukemia, acute myeloid leukemia, and solid tumors; CDC25 regulates cell cycle progression and is overexpressed in a number of human cancers; and the PRLs are overexpressed in cancer and have been linked to tumor metastasis. Hence, inhibitors directed against these PTPs can serve as potential novel anti-cancer agents. This chapter provides an overview of the mechanisms of these oncogenic PTPs in promoting cancer, the approaches for inhibitor discovery, as well as the current status of drug development targeting these phosphatases.",
keywords = "Cancer, CDC25, Drug development, Inhibitor design, Potency and specificity, PRL, Protein-tyrosine phosphatase, PTP1B, SHP2, Therapeutics",
author = "Rongjun He and Zhong-Yin Zhang",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-3649-6_13",
language = "English (US)",
isbn = "9781493936472",
pages = "335--353",
booktitle = "Protein Tyrosine Phosphatases in Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Current status of PTP-based therapeutics

AU - He, Rongjun

AU - Zhang, Zhong-Yin

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Protein tyrosine phosphorylation regulates virtually all aspects of cellular function. Proper levels of protein tyrosine phosphorylation are controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs). Deregulation of tyrosine phosphorylation-mediated signaling is a major cause of cancer. Indeed, PTKs represent an important class of anti-cancer drug targets with more than 20 drugs already approved by the FDA. Several PTPs are also implicated in tumor onset, progression and metastasis, and have attracted attention as potential therapeutic targets for cancer treatment. The most recognized members of the PTP family include PTP1B, SHP2, CDC25, and PRLs. PTP1B plays a positive role in breast cancer progression; SHP2 germ line and somatic gain-of-function mutations cause Noonan Syndrome, juvenile myelomonocytic leukemia, acute myeloid leukemia, and solid tumors; CDC25 regulates cell cycle progression and is overexpressed in a number of human cancers; and the PRLs are overexpressed in cancer and have been linked to tumor metastasis. Hence, inhibitors directed against these PTPs can serve as potential novel anti-cancer agents. This chapter provides an overview of the mechanisms of these oncogenic PTPs in promoting cancer, the approaches for inhibitor discovery, as well as the current status of drug development targeting these phosphatases.

AB - Protein tyrosine phosphorylation regulates virtually all aspects of cellular function. Proper levels of protein tyrosine phosphorylation are controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs). Deregulation of tyrosine phosphorylation-mediated signaling is a major cause of cancer. Indeed, PTKs represent an important class of anti-cancer drug targets with more than 20 drugs already approved by the FDA. Several PTPs are also implicated in tumor onset, progression and metastasis, and have attracted attention as potential therapeutic targets for cancer treatment. The most recognized members of the PTP family include PTP1B, SHP2, CDC25, and PRLs. PTP1B plays a positive role in breast cancer progression; SHP2 germ line and somatic gain-of-function mutations cause Noonan Syndrome, juvenile myelomonocytic leukemia, acute myeloid leukemia, and solid tumors; CDC25 regulates cell cycle progression and is overexpressed in a number of human cancers; and the PRLs are overexpressed in cancer and have been linked to tumor metastasis. Hence, inhibitors directed against these PTPs can serve as potential novel anti-cancer agents. This chapter provides an overview of the mechanisms of these oncogenic PTPs in promoting cancer, the approaches for inhibitor discovery, as well as the current status of drug development targeting these phosphatases.

KW - Cancer

KW - CDC25

KW - Drug development

KW - Inhibitor design

KW - Potency and specificity

KW - PRL

KW - Protein-tyrosine phosphatase

KW - PTP1B

KW - SHP2

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85006721974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006721974&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3649-6_13

DO - 10.1007/978-1-4939-3649-6_13

M3 - Chapter

SN - 9781493936472

SP - 335

EP - 353

BT - Protein Tyrosine Phosphatases in Cancer

PB - Springer New York

ER -